Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:02 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,660 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Whole blood Clear all
Completed Not applicable Interventional

Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer

NCT03262831
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast
Interventions
Yoga, Blood draw, FACT-G questionnaire, Weight measurement, Recent Physical Activity Questionnaire, NHANES Food Questionnaire
Other · Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Nov 2, 2026, 2:02 PM EST
Withdrawn Phase 1 Interventional

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

NCT03920631
View directory record Official record
Conditions
B Cell Lymphomas
Interventions
Nivolumab, Microtransplantation
Drug · Biological
Lead sponsor
Ahmed Galal, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Nov 2, 2026, 2:02 PM EST
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

NCT01266031
View directory record Official record
Conditions
Malignant Glioma, Recurrent Glioblastoma
Interventions
vorinostat, bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Nov 2, 2026, 2:02 PM EST
Completed Phase 1 Interventional

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

NCT00606437
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions
Total Body Irradiation with Fludarabine in UCB Transplants
Procedure
Lead sponsor
Duke University
Other
Eligibility
14 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Nov 2, 2026, 2:02 PM EST
Completed No phase listed Observational

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

NCT01339481
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Anniston, Alabama • Palm Harbor, Florida • Wheaton, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Nov 2, 2026, 2:02 PM EST
Terminated Phase 4 Interventional Accepts healthy volunteers

HCV Test and Treat Utilizing Simplified HCV Patient Education

NCT05582681
View directory record Official record
Conditions
Hepatitis C
Interventions
Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir
Diagnostic Test · Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Long Island City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Nov 2, 2026, 2:02 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 2, 2026, 2:02 PM EST
Terminated No phase listed Observational

Adult MDW Dual Cut-Off Accuracy Study

NCT06885528
View directory record Official record
Conditions
Sepsis
Interventions
Complete Blood Count with differential
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Kansas • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Recruiting Phase 2 Interventional

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT03258567
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, Lymphoproliferative
Interventions
Nivolumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Completed Not applicable Interventional Results available

BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease

NCT02228564
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Arterial Occlusive Disease
Interventions
Percutaneous transluminal angioplasty (PTA), LIFESTREAM™ covered stent
Procedure · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 2, 2026, 2:02 PM EST
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

NCT00054132
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Bevacizumab, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Nov 2, 2026, 2:02 PM EST
Recruiting No phase listed Observational

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

NCT05705531
View directory record Official record
Conditions
Cardiovascular Disorder, Classic Hodgkin Lymphoma, Clonal Hematopoiesis
Interventions
Archive Sample Retrieval, Biospecimen Collection, Electronic Health Record Review, Magnetic Resonance Imaging, Survey Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
7 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

NCT00360737
View directory record Official record
Conditions
Healthy
Interventions
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Nov 2, 2026, 2:02 PM EST
Not listed Early Phase 1 Interventional

Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

NCT03292445
View directory record Official record
Conditions
Immune Tolerance
Interventions
Immune tolerance after kidney transplant, Donor blood stem cells and T cells
Procedure · Drug
Lead sponsor
Samuel Strober
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Nov 2, 2026, 2:02 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Computer Assisted Learning (CAL) Module Use for Re-training of Blood Pressure Measurements by Physical Therapy Students

NCT05915039
View directory record Official record
Conditions
Blood Pressure
Interventions
Computer Assisted Learning (CAL) Module
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Nov 2, 2026, 2:02 PM EST
Enrolling by invitation No phase listed Observational

RNA to the RESCUE: Evaluation to Assess the Clinical Utility of RNA Sequencing in Establishing a Genetic Diagnosis or Adjudicating a Previously Established Genetic Diagnosis.

NCT07787975
View directory record Official record
Conditions
Genetic Conditions, Genetic Disorders
Interventions
RNA sequencing
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Terminated Phase 2 Interventional Results available

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

NCT03115801
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Nivolumab, Atezolizumab, Radiation & immunotherapy, Pembrolizumab
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Nov 2, 2026, 2:02 PM EST
Recruiting No phase listed Observational

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT06093867
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Completed No phase listed Observational

ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)

NCT05347992
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Nov 2, 2026, 2:02 PM EST
Completed No phase listed Observational

Determination of Amifostine Levels During Radiation Therapy

NCT00286611
View directory record Official record
Conditions
Cancer
Interventions
Blood and salivary sampling of amifostine
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 10, 2008 · Synced Nov 2, 2026, 2:02 PM EST
Active, not recruiting Phase 2 Interventional

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03909334
View directory record Official record
Conditions
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
Interventions
Osimertinib, Ramucirumab
Drug
Lead sponsor
Xiuning Le
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Withdrawn Not applicable Interventional

Digital Diabetes Prevention Program Study

NCT06137963
View directory record Official record
Conditions
PreDiabetes
Interventions
Transform10 Diabetes Prevention Program
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 2, 2026, 2:02 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Early-onset Dementia

NCT04906863
View directory record Official record
Conditions
Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
Interventions
Blood draw, Neurocognitive testing, Medical questionnaire
Genetic · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 2, 2026, 2:02 PM EST
Completed Phase 2 Interventional Results available

Meloxicam vs Placebo for Mobilization

NCT02003625
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
Interventions
GCSF, meloxicam, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Nov 2, 2026, 2:02 PM EST